Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances
MD Egeberg, CY Oh, JL Bainbridge - Clinical therapeutics, 2012 - Elsevier
BACKGROUND: Medication used to treat multiple sclerosis (MS) can be categorized as
disease-modifying therapies, symptomatic therapies, or treatment of acute exacerbations.
Dalfampridine is the first symptomatic therapy approved by the Food and Drug
Administration to improve walking in patients with MS. OBJECTIVE: This article reviews the
pharmacology, pharmacodynamic properties, and pharmacokinetic properties of
dalfampridine, as well as its clinical efficacy, safety profile, pharmacoeconomic …
disease-modifying therapies, symptomatic therapies, or treatment of acute exacerbations.
Dalfampridine is the first symptomatic therapy approved by the Food and Drug
Administration to improve walking in patients with MS. OBJECTIVE: This article reviews the
pharmacology, pharmacodynamic properties, and pharmacokinetic properties of
dalfampridine, as well as its clinical efficacy, safety profile, pharmacoeconomic …
以上显示的是最相近的搜索结果。 查看全部搜索结果